BioPharma CreditLSE:BPCR +0.63%49 OCF Margin % is 98.42% as of Dec. 2025, which is 4% above its 10-year median of 94.97. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,457 Asset Management companies, BioPharma Credit ranks better than 73.78% on this metric.
The historical rank and industry rank for BioPharma Credit's OCF Margin % or its related term are showing as below:
LSE:BPCR'
s OCF Margin % Range Over the Past 10 Years
Min: 63.57 Med: 94.97 Max: 111.49
Current: 68.98
During the past 9 years, the highest OCF Margin % of BioPharma Credit was 111.49%. The lowest was 63.57%. And the median was 94.97%.
LSE:BPCR's OCF Margin % is ranked better than 73.78% of 1457
companies
in the Asset Management industry
Industry Median: 15.58
vs LSE:BPCR: 68.98
BioPharma Credit OCF Margin % Related Terms
BioPharma Credit OCF Margin % Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit OCF Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's OCF Margin % distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a OCF Margin % of 98.42% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioPharma Credit and its competitors. This is near median its historical median of 94.97. Over the past decade, BioPharma Credit's OCF Margin % has ranged from 63.57 to 111.49. According to the industry distribution chart, BioPharma Credit ranks #382 out of 1457 companies in the Asset Management industry, placing it in the top 26.2%.
Is BioPharma Credit's OCF Margin % too high?
BioPharma Credit's current OCF Margin % of 98.42% is near median its 10-year median of 94.97. Over the past 10 years, this metric has ranged from a low of 63.57 to a high of 111.49. The Asset Management industry median OCF Margin % is 15.58. BioPharma Credit's value of 98.42% is 531.7% above this industry median. Based on the distribution chart, BioPharma Credit ranks #382 out of 1457 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's OCF Margin % compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #382 out of 1457 companies for OCF Margin %. This puts BioPharma Credit in the upper half of its industry. The industry median OCF Margin % is 15.58. BioPharma Credit's value of 98.42% is 531.7% above this benchmark. Historically, BioPharma Credit's own OCF Margin % has ranged from 63.57 to 111.49 over the past decade. While the company's 10-year median is 94.97 vs. the industry median of 15.58, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for an Asset Management company?
The median OCF Margin % among Asset Management companies is 15.58, based on 1,457 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current OCF Margin % of 98.42% is 531.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median OCF Margin % is 15.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current OCF Margin % is 98.42%, which is near median its own 10-year median of 94.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current OCF Margin % is 98.42%, which is near median its 10-year median of 94.97 and 531.7% above the Asset Management industry median of 15.58. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current OCF Margin % is 98.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
OCF Margin %: 98.42% (near median its 10-year median of 94.97)
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
Industry Position: 531.7% above the Asset Management median (#382 of 1457)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
